Spinout Active LTD

Company profile

Ailsevax Limited

AilseVax

Ailsevaxis based on the 3 core elements: neo-antigens discovery, cancer vaccine development, effective adjuvants and delivery platforms. AilseVax are developing innovations across all three domains to develop the next generation of cancer vaccine therapies.Founded by oncologists, immunologists, data scientists and an experienced management team with excellent track-record in building multiple successful life sciences ventures.

CRN
NI681133
Founded
2021
Age
4

Overview

Browse spinouts
Legal name
AILSEBIO LIMITED
Region
Northern Ireland
Registered address
C/O KPMG, THE SOLOIST BUILDING
1 LANYON PLACE
BELFAST
UNITED KINGDOM
BT1 3LP
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

08 Aug
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

25 Jul
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

27 Sep
2024

Accounts With Accounts Type Total Exemption Full

Accounts Awaiting analysis

AA | Transaction MzQzNzU0ODU0MmFkaXF6a2N4

Published 27 Sep 2024 03:03

28 Jul
2021

Incorporated

Inception

Company registered at Companies House

Spinout profile

3 entries

Company description

AilseVax develops technology, such as an antigen discovery platform and adjuvant technology, with the aim to create new cancer vaccines.

New spin out company from QUB and TCD to develop next generation cancer vaccines

Project impact

N/A

AilseVax
2021
AILSEVAX LIMITED
2021

Public funding

3 awards
First funded
2022
Funded years
2022, 2024
Age at first award
0 years

Projects

2024 Collaborative R&D Lead participant

Antigen-to-Surface Enhancement Technology (ASET); an antigen presentation boosting platform for mRNA vaccines

1 Jun 2024 to 30 Nov 2025

Awarded
£217,248
Total cost £310,354

The success of mRNA vaccines against SARS-CoV-2 highlights the revolutionary capabilities of this technology. Its efficacy in combatting other diseases like malaria and respiratory syncytial virus is also ground-breaking, and these advancements are now helping to fuel the development of mRNA-based vaccines targeting cancer. However, despite their promise,...

2024 Launchpad Lead participant

Scaling a novel nanoparticle vaccine adjuvant for clinical development

1 May 2024 to 31 Mar 2025

Awarded
£99,903
Total cost £99,903

AilseVax Ltd is a vaccine-focussed company developing new innovations in vaccine design and formulation. AilseVax is a spinout micro-company from Queen's University Belfast trading in Belfast. Up to this point, AilseVax has been focussed on the generation of novel cancer vaccines. In the lead up to this current application, AilseVax has developed an excit...

2022 Collaborative R&D Lead participant

AltRNA8V antigens for Cancer Vaccines

1 May 2022 to 30 Apr 2024

Awarded
£309,925
Total cost £442,750

The COVID pandemic has unsurprisingly awakened new interest in the power of vaccine technologies. One disease area where vaccination holds particular promise is cancer. Cancer remains a major problem, with one in every two people in the UK now predicted to get cancer in their lifetimes. This has a considerable impact on individual lives and livelihoods, e...

Product types

Collaborative R&D Launchpad